Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review

doi:10.3748/wjg.v19.i47.8940

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 47

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7435)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

514

HTML

4764

Figures (1-1)

186

Tables (1-4)

155

Sum=5619

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

935

Download

881

Sum=1816

Dec 21, 2013 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 21, 2013; 19(47): 8940-8948
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8940

Table 1 Overview of representative clinical trials of hepatitis C virus NS3/4A protease inhibitors

Name of drug (other name)	G	Trial phase	Features of clinical trials (ClinicalTrials.gov Identifier)
Telaprevir (VX-950)	1	FDA approved	Telaprevir, PEG-IFN alpha-2a, RBV
	1b	3	Telaprevir, Daclatasvir (NS5A inhibitor), PEG-IFN alpha-2a, RBV (COMMAND-3) (NCT01492426)
	1	3	Telaprevir, PEG-IFN lambda-1a, RBV (NCT01598090)
	4	2	Telaprevir, PEG-IFN alpha-2a, RBV (NCT0050801)
Boceprevir	1	FDA approved	Boceprevir, PEG-IFN alpha-2a, RBV
(SCH 503034)Simeprevir (TMC435)	1	3	Simeprevir, PEG-IFN alpha-2a, RBV (NCT01290731)
(SCH 503034)Simeprevir (TMC435)	1b/4	2	Simeprevir, IDEX719 (NS5A inhibitor), RBV (NCT01852604)
Faldaprevir (BI201335)	1	3	Faldaprevir, PEG-IFN alpha-2a, RBV
	1a	2	Faldaprevir, PPI-668 (NS5A inhibitor), BI207127 (non-nucleoside NS5B inhibitor), (+ RBV) (NCT01859962)
	1b	2	Faldaprevir, BI207127, RBV (NCT01858961)
Danoprevir (ITMN-191)	1	2	Danoprevir, PEG-IFN alpha-2a, RBV (NCT00963885)
	1/4	2	Danoprevir, Ritonavir, PEG-IFN alpha-2a, RBV (NCT01220947)
	1	2	Danoprevir, Ritonavir, RO5024048 (NS5B inhibitor), RBV, (± PEG-IFN alpha-2a) (NCT01331850)
Vaniprevir (MK-7900)	1	3	Vaniprevir, PEG-IFN alpha-2b, RBV (NCT01405937)
Asunaprevir (BMS-650032)	1	3	Asunaprevir, Daclatasvir (NCT01497834)
	1	2	Asunaprevir, PEG-IFN lambda, RBV (NCT01309932)
	1/4	2	Asunaprevir, PEG-IFN alpha-2a, RBV (NCT01030432)
	1a/1b/4	2	Asunaprevir, Daclatasvir, BMS-791325 (NS5B inhibitor) (NCT01455090)

Data from http://www.clinicaltrials.gov accessed on September 8, 2013. FDA: United States Food and Drug Administration; G: Genotype; HCV: Hepatitis C virus; PEG-IFN: Peginterferon; RBV: Ribavirin.

Citation: Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948
URL: https://www.wjgnet.com/1007-9327/full/v19/i47/8940.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i47.8940